Mechanisms of resistance to RAF inhibitors in melanoma

The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority patients. However, initial responses were followed by subsequent tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Aplin, Andrew E., Kaplan, Fred M., Shao, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156870/
https://www.ncbi.nlm.nih.gov/pubmed/21593776
http://dx.doi.org/10.1038/jid.2011.147
_version_ 1782210246363578368
author Aplin, Andrew E.
Kaplan, Fred M.
Shao, Yongping
author_facet Aplin, Andrew E.
Kaplan, Fred M.
Shao, Yongping
author_sort Aplin, Andrew E.
collection PubMed
description The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority patients. However, initial responses were followed by subsequent tumor re-growth and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors.
format Online
Article
Text
id pubmed-3156870
institution National Center for Biotechnology Information
language English
publishDate 2011
record_format MEDLINE/PubMed
spelling pubmed-31568702012-03-01 Mechanisms of resistance to RAF inhibitors in melanoma Aplin, Andrew E. Kaplan, Fred M. Shao, Yongping J Invest Dermatol Article The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority patients. However, initial responses were followed by subsequent tumor re-growth and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors. 2011-05-19 2011-09 /pmc/articles/PMC3156870/ /pubmed/21593776 http://dx.doi.org/10.1038/jid.2011.147 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Aplin, Andrew E.
Kaplan, Fred M.
Shao, Yongping
Mechanisms of resistance to RAF inhibitors in melanoma
title Mechanisms of resistance to RAF inhibitors in melanoma
title_full Mechanisms of resistance to RAF inhibitors in melanoma
title_fullStr Mechanisms of resistance to RAF inhibitors in melanoma
title_full_unstemmed Mechanisms of resistance to RAF inhibitors in melanoma
title_short Mechanisms of resistance to RAF inhibitors in melanoma
title_sort mechanisms of resistance to raf inhibitors in melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156870/
https://www.ncbi.nlm.nih.gov/pubmed/21593776
http://dx.doi.org/10.1038/jid.2011.147
work_keys_str_mv AT aplinandrewe mechanismsofresistancetorafinhibitorsinmelanoma
AT kaplanfredm mechanismsofresistancetorafinhibitorsinmelanoma
AT shaoyongping mechanismsofresistancetorafinhibitorsinmelanoma

Ejemplares similares